Article · Wikipedia archive · Last revised May 30, 2026

Arrow declaration

In UK patent litigation, an Arrow declaration is a declaration or order sought, for reasons of legal certainty, from a court that a product to be launched was old or obvious in patent law terms at a particular date, so that the product cannot be affected by any later granted patent, which would itself necessarily also either lack novelty or inventive step. The order is named after Arrow Generics Ltd. v Merck & Co Inc [2007] EWHC 1900 (Pat), in which it was originally suggested that this mechanism would be available as a declaratory relief. Such a declaration was granted for the first time in Fujifilm Kyowa Kirin Biologics Company Ltd v Abbvie Biotechnology Ltd [2017] EWHC 395 (Pat), Patents Court, England, 3 March 2017.

Last revised
May 30, 2026
Read time
≈ 2 min
Length
432 w
Citations
9
Source

In UK patent litigation, an Arrow declaration is a declaration or order sought, for reasons of legal certainty, from a court that a product (or process) to be launched was old (i.e., not novel) or obvious in patent law terms at a particular date, so that the product (or process) cannot be affected by (i.e., cannot infringe) any later granted patent, which would itself necessarily also either lack novelty or inventive step.1234 The order is named after Arrow Generics Ltd. v Merck & Co Inc [2007] EWHC 1900 (Pat), in which it was originally suggested that this mechanism would be available as a declaratory relief.135 Such a declaration was granted for the first time in Fujifilm Kyowa Kirin Biologics Company Ltd v Abbvie Biotechnology Ltd [2017] EWHC 395 (Pat), Patents Court, England, 3 March 2017.5

The defense is similar to a so-called "Gillette defense", i.e. "the argument in infringement proceedings (...) that the defendant's product implements prior art technology, such that any patent which it infringes must be invalid."1

See also

See also

References

References

  1. Brazell, Lorna (1 September 2017). "Pre-emptive product patentability declarations". Pharmaceutical Patent Analyst. 6 (5): 197–200. doi:10.4155/ppa-2017-0023. ISSN 2046-8954. PMID 28818023.
  2. Adair, Dominic (1 July 2018). "Arrow declarations: here to stay or a flash in the pan?". Pharmaceutical Patent Analyst. 7 (4): 133–136. doi:10.4155/ppa-2018-0009. ISSN 2046-8954. PMID 29882713. S2CID 46983781.
  3. England, Paul (November 2019). "Arrow declarations: a creative new remedy, but what are its limits?". Pharmaceutical Patent Analyst. 8 (6): 217–219. doi:10.4155/ppa-2019-0024. PMID 31718455. S2CID 207963034.
  4. Gilbert, Penny; Kendall-Windless, Carissa; Rowlatt, Benjamin (2020). "Will Arrow Relief Take Flight?". Managing Intellectual Property. 286: 45.
  5. Daniels, Mark; Parsons, Giles (1 August 2017). "Patents Court grants declarations that dosage regimens were obvious". Journal of Intellectual Property Law & Practice. 12 (8): 624–626. doi:10.1093/jiplp/jpx112. ISSN 1747-1532.
Further reading

Further reading